Protocol Ledger

NCT07685808 · Phase II · RECRUITING

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

Interventional Phase II clinical trial protocol NCT07685808 sponsored by Regeneron Pharmaceuticals in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-07-28 Enrollment: 360 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07685808
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)360 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07685808
Protocol FieldVerified Registry Value
NCT IdentifierNCT07685808
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment360 participants (ESTIMATED)
Registered Start Date2026-07-28
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI